Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular disease, and Synfini, Inc., an agile AI foundry for small-molecule drug discovery, today announced results from a research collaboration that has produced a validated-quality lead candidate directed at MSH3, a gene increasingly understood to drive the somatic repeat expansion that paces the progression of Huntington’s disease. The companies reached the milestone in a matter of weeks. Industry benchma

Sensible Biotechnologies, a biotechnology company developing cell-based manufacturing technologies for mRNA medicines, has raised $47 million to advance and scale its platform. The financing includes a Series A and up to $20 million in non-dilutive funding from Slovakia and the European Union. The company said the funding will support the development and scale-up of its VECTOR platform, expansion of its AI-enabled mRNA design and high-throughput screening capabilities, and development of clinica

Oct. 06, 2026 -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. “We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Exec

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) Oct. 8, 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced today

Oct. 7, 2026 -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a novel siRNA therapeutic targeting INHBE (inhibin subunit beta E), with overweight and obesity as its intended future therapeutic indications. Obesity has become one of the world's most significant public health challenges, affecting more than one billion peopl

Two abstracts on long-term follow-up data of AHB-137 treatment for chronic hepatitis B have been selected for late-breaking oral presentations at The Liver Meeting® 2026. Oct. 7, 2026 -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together,"AusperBio"), a near-commercial biopharmaceutical company, today announced that two abstracts reporting long-term follow-up data of AHB-137 treatment have been selected for late-breaking oral presentations at The Liver Meeting® 2026, the annu

Matchpoint Therapeutics announced Wednesday the closing of a series B financing round that has added $150 million to the biotech's coffers in support of efforts to develop oral, small-molecule drugs for autoimmune and inflammatory diseases. The financing was co-led by Nextech Invest and Norwest, with new participants including Invus, BB Biotech, T1D Fund and BOLD Longevity Growth. In addition, existing investors Access Biotechnology, Atlas Venture, Sanofi Ventures and Digitalis Ventures also to

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 in

Shionogi & Co, headquartered in Osaka, Japan, has agreed to acquire IntraBio, a biopharmaceutical company developing and commercialising therapies for neurodegenerative diseases. IntraBio would become a wholly owned subsidiary of Shionogi Inc, a New Jersey, US-based subsidiary of Shionogi. The deal would add Aqneursa (levacetylleucine) and IntraBio’s capabilities in the rare disease area to Shionogi’s growing portfolio. Aqneursa was approved by the FDA in September 2024 for neurological manifest

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment